Yuhan Corporation operates as a pharmaceutical company in South Korea and internationally. It offers manufacturing services, such as custom manufacturing; process research and development of active pharmaceutical products (APIs) and intermediates; kilo and pilot-scale production of APIs and intermediates; commercial production of APIs and intermediates; production of chemical specialties; and analytical method development and regulatory support. The company also provides APIs and intermediates, including antibiotic, anti-thrombotic, anti-hyperlipidemics, and anti-hypertensive; and custom synthesis services through commercial supply in areas of anti-viral, anti-HIV, anti-HCV, anti-biotic, antihistamine, anti-diabetic, ß-lactamase inhibitor, CNS intermediate, PEG-compounds, and others. Yuhan Corporation was founded in 1926 and is headquartered in Seoul, South Korea.
Research context
Yuhan Corporation appears in PyInvesting’s Korea Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- KRW
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
5 years, 6 months ago
Yuhan Corporation is currently in a long term downtrend where the price is trading 0.1% below its 200 day moving average.
From a valuation standpoint, the stock is 70.8% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 2.5.
Yuhan Corporation's total revenue rose by 17.2% to $461B since the same quarter in the previous year.
Its net income has increased by 173.0% to $13B since the same quarter in the previous year.
Finally, its free cash flow fell by 161.7% to $-3B since the same quarter in the previous year.
Based on the above factors, Yuhan Corporation gets an overall score of 3/5.